L-5103 Lepetit
Categoria
L-5103 Lepetit Nombres de marca, L-5103 Lepetit Analogos
L-5103 Lepetit Marca los nombres de mezcla
L-5103 Lepetit Formula quimica
L-5103 Lepetit RX enlace
L-5103 Lepetit FDA hoja
L-5103 Lepetit MSDS (hoja de seguridad de materiales)
L-5103 Lepetit Sintesis de referencia
L-5103 Lepetit Peso molecular
L-5103 Lepetit Punto de fusion
L-5103 Lepetit H2O Solubilidad
L-5103 Lepetit Estado
L-5103 Lepetit LogP
L-5103 Lepetit Formas de dosificacion
L-5103 Lepetit Indicacion
L-5103 Lepetit Farmacologia
L-5103 Lepetit Absorcion
L-5103 Lepetit Toxicidad
L-5103 Lepetit Informacion de Pacientes
The patient should be told that rifampin may produce a reddish coloration of the urine, sweat, sputum, and tears, and the patient should be forewarned of this. Soft contact lenses may be permanently stained. The patients should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures. Patients should be instructed to take rifampin either 1 hour before or 2 hours after a meal with a full glass of water. Patients should be instructed to notify their physicians promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints. Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.
